Anzeige
Mehr »
Freitag, 01.08.2025 - Börsentäglich über 12.000 News
Der KI-Energiekollaps: Uran auf kritischem Kurs - und Foremost Clean Energy entflammt den Markt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QK1R | ISIN: KYG4987A1094 | Ticker-Symbol: 77V
Frankfurt
31.07.25 | 15:29
0,890 Euro
+9,20 % +0,075
Branche
Pharma
Aktienmarkt
ASIEN
1-Jahres-Chart
JACOBIO PHARMACEUTICALS GROUP CO LTD Chart 1 Jahr
5-Tage-Chart
JACOBIO PHARMACEUTICALS GROUP CO LTD 5-Tage-Chart
RealtimeGeldBriefZeit
0,8900,99031.07.
0,8950,98531.07.

Aktuelle News zur JACOBIO PHARMACEUTICALS GROUP Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoJACOBIO-B (01167): NEXT DAY DISCLOSURE RETURN2
24.07.JACOBIO-B (01167): VOLUNTARY ANNOUNCEMENT FURTHER INCREASE SHAREHOLDINGS OF THE PARTIES ACTING IN CONCERT1
JACOBIO PHARMACEUTICALS GROUP Aktie jetzt für 0€ handeln
21.07.JACOBIO-B (01167): VOLUNTARY ANNOUNCEMENT INCREASE SHAREHOLDINGS OF THE PARTIES ACTING IN CONCERT1
15.07.JACOBIO-B (01167): NEXT DAY DISCLOSURE RETURN1
14.07.JACOBIO-B (01167): VOLUNTARY ANNOUNCEMENT INTENTION TO CONDUCT ON-MARKET SHARE REPURCHASE1
03.07.Jacobio Pharma: Jacobio's IND for Phase I/II Clinical Trial of BET Inhibitor JAB-8263 in Autoimmune Diseases has been Accepted61BEIJING, SHANGHAI and BOSTON, July 2, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced that it has submitted the Phase I/II Investigational New Drug (IND)...
► Artikel lesen
02.07.JACOBIO-B (01167): VOLUNTARY ANNOUNCEMENT JACOBIO COMPLETED THE FIRST PATIENT DOSAGE IN THE PHASE I/IIA CLINICAL TRIAL OF PAN-KRAS INHIBITOR JAB-23E73 ...-
10.06.JACOBIO-B (01167): SEVENTH AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION2
10.06.JACOBIO-B (01167): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 10, 20251
22.05.JACOBIO-B (01167): INSIDE INFORMATION - JACOBIO'S KRAS G12C INHIBITOR GLECIRASIB APPROVED FOR MARKET LAUNCH1
14.05.JACOBIO-B (01167): FORM OF PROXY FOR THE 2025 ANNUAL GENERAL MEETING2
14.05.JACOBIO-B (01167): NOTICE OF 2025 ANNUAL GENERAL MEETING-
14.05.JACOBIO-B (01167): PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES, PROPOSED RE-ELECTION OF DIRECTORS, PROPOSED AMENDMENTS ...-
09.05.JACOBIO-B (01167): PROPOSED AMENDMENTS TO THE EXISTING MEMORANDUM AND ARTICLES OF ASSOCIATION AND ADOPTION OF THE AMENDED AND RESTATED MEMORANDUM AND ...1
09.05.JACOBIO-B (01167): VOLUNTARY ANNOUNCEMENT SHP2 INHIBITOR SITNEPROTAFIB COMBINATION THERAPY DATA PUBLISHED IN ACADEMIC JOURNAL1
30.04.JACOBIO-B (01167): VOLUNTARY ANNOUNCEMENT CHANGES IN THE INTERESTS OF THE PARTIES ACTING IN CONCERT-
25.04.JACOBIO-B (01167): NOTIFICATION LETTER AND REPLY FORM TO NON-REGISTERED SHAREHOLDERS - ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS3
25.04.JACOBIO-B (01167): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS - ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS-
24.04.JACOBIO-B (01167): 2024 ANNUAL REPORT3
16.04.JACOBIO-B (01167): NEXT DAY DISCLOSURE RETURN1
Weiter >>
24 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1